Ebola — Multi-Epitope mRNA Vaccine Candidate

Ebola virus (Zaire ebolavirus) infection is driven by key viral antigens: the glycoprotein (GP), nucleoprotein (NP) and matrix protein (VP40). This design targets multiple Ebola antigens simultaneously: immunogenic B-cell, CTL and helper T-cell epitopes are predicted from GP, NP and VP40, combined with suitable linkers and adjuvant sequences into a single multi-epitope mRNA construct, formulated for lipid nanoparticle delivery. The strategy aims at broad cellular immune recognition of several viral proteins rather than a single antigen.

Enlarge

Original uploaded scientific infographic — use the Enlarge button for a full-size view.

1. 1

   Antigen selection — target key Ebola virus antigens: GP (glycoprotein), NP (nucleoprotein) and VP40 (matrix protein).

2. 2

   Epitope prediction — identify immunogenic B-cell, CTL and helper T-cell epitopes from GP, NP and VP40.

3. 3

   Multi-epitope construct design — combine selected epitopes with suitable linkers (e.g., GPGPG, AAY) and adjuvant sequences into one construct with 5′ UTR and 3′ UTR.

4. 4

   mRNA vaccine formulation — conceptually synthesize the multi-epitope mRNA and formulate it in lipid nanoparticles (LNPs).

5. 5

   Immune activation modeling — model CD8+ T-cell (kill infected cells) and CD4+ T-cell (support durable immune response) activation against Ebola antigens.

1. 1

   The multi-epitope mRNA, delivered in an LNP, is translated by host antigen-presenting cells.

2. 2

   Ebola GP, NP and VP40 epitopes are processed and presented via MHC-I and MHC-II pathways.

3. 3

   CD8+ T cells are modeled to recognize MHC-I presented epitopes and kill infected cells (proposed cytotoxic response).

4. 4

   CD4+ T cells are modeled to recognize MHC-II presented epitopes and support a durable immune response (proposed helper response).

5. 5

   The concept is a pre-exposure immune priming design with potential broad antiviral targeting — computational only, not a proven treatment or approved vaccine.

All steps describe intended, modeled or proposed behavior — no effect above is experimentally proven or clinically demonstrated.

Ebola — Computational vaccine candidate

These projects are scientific research designs and computational proof-of-concept studies. They are not approved medical products, experimentally validated cures, or guarantees of therapeutic effectiveness.